Evaluation of Anti-Coagulant Activity of Ficus racemosa Bark Extract in Rats

Coagulation disorders such as thrombosis and stroke are major health concerns, and the use of conventional anticoagulants is often limited by adverse effects. this study evaluated the anticoagulant potential of the ethanolic extract of Ficus racemosa bark (EEFRB). in vitro analysis demonstrated significant prolongation of prothrombin time (pt) at 1 mg/ml and activated partial thromboplastin time (APTT) at 10 mg/ml. in vivo studies in rats, administered EEFRB (100, 200, and 400 mg/kg), showed increased pt (days 3 and 5), significant APTT prolongation (day 5), reduced platelet count, and extended clotting time, indicating effects on both extrinsic and intrinsic pathways. LC–MS analysis identified key bioactive compounds, including coumarin, quercetin, kaempferol, and β-sitosterol. overall, EEFRB exhibited dose-dependent anticoagulant activity comparable to warfarin, with notable efficacy at 200 and 400 mg/kg.